ZHUZF yields 5.51% · JNJ yields 2.13%● Live data
📍 ZHUZF pulled ahead of the other in Year 1
Combined, ZHUZF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ZHUZF + JNJ for your $10,000?
Zhuzhou CRRC Times Electric Co., Ltd., together with its subsidiaries, engages in the research, development, design, manufacture, and sale of railway transportation equipment products, and provision of relevant services primarily in Mainland China and internationally. The company's products include traction converter systems of rail transit vehicles, railway engineering machinery, and communication signal systems. It also produces propulsion and control systems for trains and electric vehicles, signaling systems, power supply solutions, platform screen doors, rail maintenance vehicles, marine engineering equipment, and component products for various applications. The company's products for rolling stock and railways include EMU, locomotive, and mass transit systems; and components products consist of semiconductors, resistors, reactors, radiators, sensors, power capacitors, and heatsinks. Its energy and industrial products comprise marine engineering, electric vehicle, and inverter and converter systems, as well as provides railway maintenance and construction machines. The company was formerly known as Zhuzhou CSR Times Electric Co., Ltd. and changed its name to Zhuzhou CRRC Times Electric Co., Ltd. in March 2016. The company was incorporated in 2005 and is based in Wanchai, Hong Kong. Zhuzhou CRRC Times Electric Co., Ltd. is a subsidiary of CRRC Zhuzhou Institute Co., Ltd.
Full ZHUZF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.